Otsuka Pharmaceutical Europe Ltd
9
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
11%
1 trials in Phase 3/4
33%
2 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
Role: collaborator
Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia
Role: lead
A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe
Role: lead
Predictors of Persistence in Patients With Schizophrenia Treated With Once-monthly Aripiprazole in Spain
Role: lead
An Observational Study to Describe the Adherence to the SEOM Algorithm for the Treatment of Hyponatraemia in Spain
Role: lead
An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy
Role: lead
An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH
Role: lead
Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in Italy
Role: lead
Adacolumn in Refractory UC Patients Trial
Role: lead
All 9 trials loaded